Citation Impact
Citing Papers
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Synovitis in osteoarthritis: current understanding with therapeutic implications
2017 Standout
Filgotinib: First Approval
2020
Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A
2018
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
2013
What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review
2007
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee
2012 Standout
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6
2013
Interleukin-6 and cytochrome-P450, reason for concern?
2012
OARSI guidelines for the non-surgical management of knee osteoarthritis
2014 Standout
Endometriosis
2009 Standout
Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
2014
COX-2 Inhibitors and Their Role in Gynecology
2002
IL-6 as a keystone cytokine in health and disease
2015 Standout
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
2014
Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis
2005
Management of Patients With Ulcer Bleeding
2012 Standout
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases
2016
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
2006
Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review
2007
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen
2004
RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH
2012 Standout
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
2020 Standout
Diagnosis and Treatment of Hip and Knee Osteoarthritis
2021 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
2015 Standout
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation
2016 StandoutNobel
Therapeutic Targeting of the Interleukin-6 Receptor
2011
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Temporomandibular Disorders
2008 Standout
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis
2017
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
2009
Works of A. Kivitz being referenced
Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
2006
Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
2011
A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
2017
Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip
2001
OP0023 Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study
2012
THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
2020
(214) Rofecoxib Provides Superior Relief of Pain in Osteoarthritis (OA) Compared to Celecoxib
2008
FRI0209 MORAb-022, An Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody (MAB): Results of The First Study in Patients with Mild-To-Moderate Rheumatoid Arthritis (RA)
2016